Drug-eluting stents for the treatment of coronary lesions in cardiac transplant vasculopathy: acute and mid-term clinical and angiographic outcomes

2008 ◽  
Vol 9 (4) ◽  
pp. 396-402 ◽  
Author(s):  
Giuseppe Tarantini ◽  
Enrico Favaretto ◽  
Arianna Gardin ◽  
Massimo Napodano ◽  
Gianbattista Isabella ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Cardiac Transplant ◽  
Transplant Vasculopathy ◽  
Drug Eluting ◽  
Coronary Lesions

The Role of Drug-Eluting Stents in Treating Cardiac Transplant Vasculopathy

2008 ◽  
Vol 101 (12) ◽  
pp. 1198-1199 ◽  
Author(s):  
Sarabjeet Singh ◽  
Sandeep Khosla ◽  
Vishal Gupta
Keyword(s):  
Drug Eluting Stents ◽  
Cardiac Transplant ◽  
Transplant Vasculopathy ◽  
Drug Eluting

Abstract 11491: Differences in the Development of Restenosis Over Time for Various Drug-Eluting Stents

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Kosei Tanaga
Keyword(s):  
Coronary Intervention ◽  
Drug Eluting Stents ◽  
Minimal Lumen Diameter ◽  
Percutaneous Coronary ◽  
Late Loss ◽  
Drug Eluting ◽  
Coronary Lesions ◽  
To Receive ◽  
Over Time

Objective: This study aims to compare the efficacy of sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), zotarolimus-eluting stents (ZES), and everolimus eluting stents (EES) via sequential angiographic follow-up and to reveal the development of restenosis over time. Methods: Patients were randomized to receive SES, PES, ZES, or EES, and follow-up angiography was performed at 6, 12 and 24months after percutaneous coronary intervention. Results: The baseline clinical characteristics of the patients and the coronary lesions are shown in (Table 1). In all groups, mean minimal lumen diameter decreased slightly during the 2-year period after the procedure (Figure 1). Compared with the SES group, the PES and the ZES groups showed greater late loss (LL) within 1 year. However, the SES group showed significantly greater LL compared with the other drug-eluting stents (DES) between 1 and 2 years (Figure 2). Conclusion: Serial angiographic analysis revealed differences in the rate of restenosis development over time for various DES. As DES are comprised of many components (metallic platform, alloy, drug and polymer), the progression of LL can be complex and affected by different factors.

Impact of Drug-Eluting Stents on Clinical Outcomes in Patients With Diffuse Coronary Lesions

2008 ◽  
Vol 38 (11) ◽  
pp. 612 ◽  
Author(s):  
Hyeon Gook Lee ◽  
Kook Jin Chun ◽  
Kyoung Im Cho ◽  
Dong Won Lee ◽  
Jun Hyuk Oh ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Drug Eluting Stents ◽  
Drug Eluting ◽  
Coronary Lesions

Clinical and Angiographic Outcomes After Placement of Multiple Overlapping Drug-Eluting Stents in Diffuse Coronary Lesions

2006 ◽  
Vol 98 (7) ◽  
pp. 918-922 ◽  
Author(s):  
Cheol Whan Lee ◽  
Kyoung-Ha Park ◽  
Young-Hak Kim ◽  
Myeong-Ki Hong ◽  
Jae-Joong Kim ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Drug Eluting ◽  
Coronary Lesions

scholarly journals CRT-131 First- Versus Second-generation Drug-eluting Stents Following Rotational Atherectomy In Patients With Heavily Calcified Coronary Lesions

2015 ◽  
Vol 8 (2) ◽  
pp. S17
Author(s):  
Wenjie Tian ◽  
Rebecca Torguson ◽  
Marco De Magalhaes Pereira ◽  
Thibault Lhermusier ◽  
Hideaki Ota ◽  
...  
Keyword(s):  
Second Generation ◽  
Rotational Atherectomy ◽  
Drug Eluting Stents ◽  
Drug Eluting ◽  
Coronary Lesions ◽  
Calcified Coronary Lesions
Sign in / Sign up

Export Citation Format

Share Document